A Randomized Phase II Trial Assessing Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors After Failure of All Drugs Known to be Effective

Trial Profile

A Randomized Phase II Trial Assessing Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors After Failure of All Drugs Known to be Effective

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Irinotecan (Primary) ; Sorafenib (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms NEXIRI 2-PRODIGE 27; NEXIRI-2
  • Most Recent Events

    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
    • 23 Jan 2016 Status changed from recruiting to completed as result presented at the 2016 Gastrointestinal Cancers Symposium
    • 03 Dec 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top